Why This Matters Now

A patient with primary open-angle glaucoma administers a timolol maleate eye drop twice daily, as prescribed. The instillation technique is correct: one drop applied to the lower conjunctival sac, head tilted back, punctal occlusion attempted. Within two seconds of contact with the ocular surface, the blink reflex has distributed the drop across the precorneal tear film. Within five minutes, the majority of the instilled dose has drained through the nasolacrimal duct into the nasopharynx and from there into the systemic circulation. The drug absorbed through nasal mucosa contributes little to intraocular pressure reduction. What it does contribute to are the systemic beta-blocking effects that have led prescribers to seek formulations designed to extend the time the active ingredient remains in contact with the corneal surface before being removed by the tear drainage system.

The governing variable in this scenario is not the concentration of timolol in the formulation. It is the physical behavior of the liquid on the ocular surface during the brief interval between instillation and drainage. How quickly the drop spreads across the tear film, how much of its volume is retained rather than drained, and how long drug concentration at the corneal surface remains above the threshold needed for effect are determined by the surface tension of the formulation, the wetting properties of the vehicle, and the rheological characteristics that govern how the product behaves in the dynamic environment of a blinking, tear-producing eye. For nasal drug delivery, the governing variables are analogous: the formulation must spread across and adhere to the nasal mucosa quickly enough to allow absorption before mucociliary clearance carries it toward the nasopharynx.

These are formulation science problems. The drug chemistry is not the constraint. The physical behavior of the liquid at the mucosal interface is.

The Pressures Reshaping Ophthalmic and Nasal Formulation

Several regulatory and market forces are restructuring the development environment for ophthalmic and nasal formulations, and they converge on the same formulation properties that govern wetting and residence time.

The ophthalmic generic market has expanded significantly since FDA guidance clarified acceptable approaches to demonstrating bioequivalence for ophthalmic solutions and suspensions. For certain product types, demonstrating bioequivalence requires showing that a formulation behaves equivalently at the ocular surface, not merely that it contains the same active ingredient at the same concentration. Surface tension and wetting properties are among the formulation characteristics that submissions must address, because differences in these properties between a generic and its reference listed drug can affect drug permeation through the corneal epithelium even when the labeled concentration is identical.

Benzalkonium chloride, the most widely used preservative in preserved ophthalmic preparations, has come under sustained regulatory and clinical scrutiny. BAC disrupts the lipid layer of the precorneal tear film, damages corneal epithelial cells with chronic exposure, and exacerbates the symptoms of dry eye disease in a patient population already at elevated risk. Regulators in several markets have issued guidance encouraging the development of preservative-free alternatives for products intended for long-term use. The shift toward preservative-free multi-dose systems introduces its own formulation challenges: the compound being removed simultaneously served as a surfactant contributing to surface tension control and as a preservative, and replacing only one of those functions without affecting the other is rarely straightforward.

Nasal drug delivery has expanded beyond traditional decongestant and corticosteroid applications. Intranasal delivery of peptides, small-molecule drugs, vaccines, and compounds targeting the nose-to-brain pathway for central nervous system access has created demand for formulations optimized for nasal mucosal contact and absorption rather than simply for deposition. Each application places different requirements on surface tension, viscosity, and mucoadhesive properties, because the residence time requirement and the absorption target differ across indications.

The Physics of Wetting

The ability of a liquid to spread across a surface is governed by the balance of surface and interfacial forces at the contact line where liquid, surface, and surrounding medium meet. Surface tension is a measure of the cohesive forces within a liquid. A liquid with high surface tension pulls inward on itself, which causes it to bead on surfaces rather than spread. A liquid with lower surface tension has weaker cohesive forces and covers more surface area per unit of volume dispensed.

The relationship between a liquid's surface tension and its tendency to spread on a given surface is described in terms of the contact angle: the angle between the liquid-surface interface and the liquid-vapor interface at the contact line. A small contact angle indicates good wetting, the liquid spreads and maintains broad contact with the surface. A large contact angle indicates poor wetting where the liquid beads, contacts a smaller surface area, and is more easily displaced. For ophthalmic formulations, the target surface is the corneal epithelium overlaid by the precorneal tear film, which has a surface tension in the range of 43 to 46 millinewtons per meter. A formulation with surface tension above this range will not spread as readily across the tear film and may resist integration with the tear layer, reducing the effective area of drug deposition. A formulation engineered to a surface tension closer to that of the tear film integrates more rapidly, spreads to cover a larger surface area, and delivers drug to more of the available absorptive surface per dose.

For nasal formulations, the target surface is the respiratory and olfactory epithelium covered by a mucus layer with its own surface tension and rheological properties. The nasal mucosa is more complex geometrically than the corneal surface, and the requirement for the formulation to contact the epithelium through the mucus layer adds an additional wetting step. Formulations that do not reduce surface tension enough to penetrate the mucus layer efficiently remain at the mucosal surface without achieving the interfacial contact that drives absorption. Formulations that reduce surface tension too aggressively may alter the structural integrity of the mucus gel, potentially accelerating mucociliary clearance and paradoxically reducing residence time.

Residence Time: The Window That Determines Efficacy

The precorneal tear film holds approximately seven microliters of fluid under normal conditions. A standard ophthalmic drop contains between 25 and 50 microliters. The excess over what the precorneal space can retain drains within seconds via the nasolacrimal duct. Normal tear turnover removes approximately 16 percent of the precorneal fluid volume per minute, which means that even the fraction of the instilled dose that initially integrates with the tear film is progressively diluted and drained over the following minutes. The window during which drug concentration at the corneal surface exceeds the minimum needed for effect is short, and extending that window is one of the primary objectives of ophthalmic formulation design. The net result for most conventional ophthalmic drops is that only one to five percent of the instilled dose is ultimately absorbed across the corneal epithelium into the anterior chamber.

For nasal drug delivery, the analogous constraint is mucociliary clearance. The ciliated epithelium lining most of the nasal cavity moves mucus toward the nasopharynx at approximately five to six millimeters per minute. A formulation deposited on the nasal epithelium has a residence time limited by this clearance rate unless the vehicle is designed to adhere to or penetrate the mucus layer in a way that resists the mechanical transport of ciliary beating. Residence time directly affects the absorbed dose for drugs whose nasal bioavailability depends on prolonged mucosal contact, including compounds delivered intranasally for systemic effect or for nose-to-brain transport.

Both constraints point to the same formulation requirement: the vehicle must remain in contact with the target tissue longer than drainage or clearance mechanisms would otherwise allow, without compromising the wetting properties needed to achieve initial contact in the first place. This is not a single-variable problem.

Viscosity as a Residence Time Tool

Increasing the viscosity of an ophthalmic or nasal formulation slows drainage and clearance, extending the time drug is available for absorption. Polymeric viscosity-enhancing agents, including hydroxypropyl methylcellulose, carboxymethylcellulose, polyvinyl alcohol, carbopol, and hyaluronic acid, are widely used for this purpose. Their mechanism extends beyond simple viscosity elevation: many of these polymers interact with the mucin glycoproteins of the tear film or nasal mucus through non-covalent interactions including hydrogen bonding and electrostatic attraction, producing a degree of mucoadhesion that resists drainage more effectively than viscosity alone would predict.

The trade-off is patient tolerance. In ophthalmic applications, formulations above a certain viscosity threshold cause transient blurred vision immediately after instillation, because the polymer film that coats the cornea refracts light differently than the normal tear film. Patients who experience this effect often avoid the formulation or instill smaller doses than prescribed, which defeats the purpose of the viscosity enhancement. For nasal formulations, excessive viscosity can reduce spray atomization quality, affecting the droplet size distribution and deposition pattern in the nasal cavity. The optimal viscosity is the value that maximizes residence time and drug contact within the tolerance limits set by patient experience and the physical requirements of the delivery device.

Hyaluronic acid has attracted particular interest for ophthalmic applications because it mimics the viscoelastic properties of the precorneal tear film more closely than most synthetic polymers, and because it has well-documented mucoadhesive properties with a favorable tolerability profile for chronic use. Its behavior in formulation is nonetheless complex: concentration-dependent changes in rheological properties, interactions with other formulation components, and the dependence of its mucoadhesive behavior on molecular weight require that its inclusion be treated as a design variable to be optimized rather than a fixed excipient choice.

Preservatives and Surface-Active Compounds

The preservative system in a multi-dose ophthalmic or nasal preparation is not a passive component. Benzalkonium chloride functions as a cationic surfactant. Its presence lowers surface tension, which is in principle useful for wetting, but it also disrupts the tear film lipid layer that normally retards evaporative water loss from the ocular surface. This dual function means that changes to the BAC concentration change both the preservative efficacy and the surface tension simultaneously. Reducing BAC to minimize its cytotoxic effects on the corneal epithelium requires either accepting a higher surface tension or introducing an alternative surface-active component to maintain wetting properties while using a less cytotoxic primary preservative.

Alternative preservative systems introduce their own surface activity and formulation interactions. Polyquaternium-1 and sodium perborate have been developed as lower-toxicity alternatives to BAC, but their surface tension contributions differ from BAC in ways that affect the wetting profile of the finished formulation. Preservative-free systems avoid the cytotoxicity concern but require device designs such as unit-dose containers or multi-dose airless dispensers that prevent contamination without relying on antimicrobial compounds, and the physical formulation must be compatible with these devices in ways that introduce materials compatibility as an additional design constraint.

The selection and concentration of the surfactant system therefore affects surface tension, preservative function, tear film stability, drug permeation through the epithelium, and long-term tolerability, all simultaneously. These effects cannot be decoupled by adjusting surfactant concentration alone.

Why These Properties Cannot Be Optimized Independently

The coupling between surface tension, viscosity, preservative function, and patient tolerability makes ophthalmic and nasal formulation development resistant to sequential, one-variable-at-a-time approaches.

Consider the constraint set facing a formulator developing a preservative-free alternative to a BAC-preserved ophthalmic solution. The original formulation relied on BAC for both preservative efficacy and surface tension contribution. Removing BAC requires a different preservative system, which changes the surface tension of the formulation. To restore wetting properties, a nonionic surfactant is added. The surfactant selected has its own interaction with the corneal epithelium and with the polymeric viscosity enhancer already in the formulation; the polymer-surfactant interaction changes the viscosity profile of the finished product.

Restoring the original viscosity requires adjusting the polymer concentration, which changes the mucoadhesive behavior and the residence time profile. Adjusting the polymer concentration changes the osmolality of the formulation, which affects the comfort response on instillation. The formulation that emerges may match the surface tension and viscosity of the original on individual measurements while having a different wetting profile in practice, because the interactions between components produce different behavior at the corneal surface than measurements of individual properties would predict.

For nasal formulations, analogous coupling exists between surfactant content, mucoadhesive polymer, spray pump design, and deposition pattern. The droplet size produced by the pump at a given viscosity determines where in the nasal cavity the formulation deposits. Changing viscosity to extend residence time changes the droplet size distribution, which changes the deposition pattern, which changes the absorption surface available to the drug. None of these adjustments is independent of the others.

Where Predictive Tools Change the Approach

Traditional ophthalmic and nasal formulation development iterates through formulate, characterize, and evaluate. Surface tension, viscosity, and preservative efficacy are measured, and in vitro or ex vivo studies assess wetting and permeation. When a parameter is out of specification, the composition is adjusted and the process repeats. For programs where the design space is well-characterized, this approach works within a reasonable timeline. For programs where multiple excipients are changing simultaneously, where surface tension and wetting must be met alongside new regulatory constraints on preservative use, or where component interactions are not captured in simple mixture models, the cycle becomes slow and resource-intensive in proportion to the complexity.

Predictive tools that estimate surface tension from formulation composition offer an earlier decision point. FastFormulator's Virtual Surface Tensiometer Chamber uses physicochemical models to estimate how the surface tension of an ophthalmic or nasal formulation will respond to changes in surfactant type, concentration, and combination before any material is prepared. This allows development teams to screen formulation candidates for surface tension targets computationally, identifying the composition ranges most likely to achieve the wetting profile needed for adequate precorneal or nasal mucosal coverage before committing to the physical preparation and characterization cycle. For programs where the surfactant system is the primary variable being adjusted, whether for preservative substitution, tolerability improvement, or bioequivalence demonstration, predicting surface tension behavior from composition reduces the number of experimental iterations needed to enter the viable formulation space and directs physical testing toward the candidates most likely to succeed.

Takeaways

Ophthalmic and nasal drug delivery share a fundamental constraint: the formulation has seconds to minutes to achieve adequate contact with the target tissue before drainage or mucociliary clearance removes it from the absorption site. Whether that window is sufficient to deliver a therapeutic dose is not determined primarily by the drug's potency or its concentration in the formulation. It is determined by whether the liquid spreads adequately across the mucosal surface, whether it resists drainage long enough for absorption to occur, and whether the physical interactions between the vehicle and the mucosal environment support those processes. Surface tension and wetting properties are not secondary specifications to confirm at the end of development. They are the primary performance parameters through which the formulation delivers on its therapeutic intent.

The difficulty in optimizing these properties lies in their mutual dependence. The surfactant that lowers surface tension to improve wetting is often also the preservative that must be minimized for tolerability. The polymer that increases viscosity to extend residence time is also the component whose concentration most affects the comfort response on instillation and the behavior of the spray in the delivery device. The tonicity agents that maintain comfort affect osmotic driving forces at the epithelial surface in ways that interact with drug permeation. No single parameter can be brought to specification without tracking its effects on the others. For formulation teams working under reformulation pressure, bioequivalence constraints, or regulatory expectations for preservative reduction, this coupling makes the design space navigable only by treating the formulation as an interconnected system rather than a collection of independent specifications.

Predictive tools built on physicochemical models of surface tension and wetting behavior offer a way to enter the viable formulation space before experimental resources are committed at scale. By screening surfactant systems and polymer concentrations for their surface tension and wetting implications computationally, development teams can focus their physical preparation and characterization work on the candidate formulations most likely to achieve the required behavior at the mucosal surface. For ophthalmic and nasal programs where the relationship between formulation composition and surface behavior is the rate-limiting question in development, this shift in when the earliest reliable answer arrives can meaningfully compress the path from formulation concept to a product that performs consistently where it is designed to perform: at the tissue surface, in the first few seconds after delivery.

References

• Urtti, A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Advanced Drug Delivery Reviews, 58(11), 1131–1135.
• Mishima, S., Gasset, A., Klyce, S.D. and Baum, J.L. (1966). Determination of tear volume and tear flow. Investigative Ophthalmology, 5(3), 264–276.
• Baudouin, C., Labbé, A., Liang, H., Pauly, A. and Brignole-Baudouin, F. (2010). Preservatives in eyedrops: the good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312–334.
• Ludwig, A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews, 57(11), 1595–1639.
• Sasaki, H., Yamamura, K., Nishida, K., Nakamura, J. and Ichikawa, M. (1996). Delivery of drugs to the eye by topical application. Progress in Retinal and Eye Research, 15(2), 583–620.
• Illum, L. (2003). Nasal drug delivery: possibilities, problems and solutions. Journal of Controlled Release, 87(1–3), 187–198.
• Djupesland, P.G. (2013). Nasal drug delivery devices: characteristics and performance in a clinical perspective. Drug Delivery and Translational Research, 3(1), 42–62.
• Bhatt, D.L. et al. (on behalf of the PROTECT Investigators). Ophthalmic drug delivery: a review of innovation and the unmet clinical need. Clinical Ophthalmology, 13, 2033–2047.
• Ong, B.L., Larke, J.R. and Lim, J. (1991). Tear flow, evaporation, and composition after contact lens wear. Optometry and Vision Science, 68(9), 693–697.
• Rowe, R.C., Sheskey, P.J. and Quinn, M.E. (Eds.) (2009). Handbook of Pharmaceutical Excipients, 6th Edition. Pharmaceutical Press, London.